adoptive cell therapies (Novartis)
90
Structured Review
Novartis
adoptive cell therapies
Adoptive Cell Therapies, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/adoptive+cell+therapies/adoptive+cell+therapies/pmc12051123-245-9-24
Average 90 stars, based on 1 article reviews
Adoptive Cell Therapies, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/adoptive+cell+therapies/adoptive+cell+therapies/pmc12051123-245-9-24
Average 90 stars, based on 1 article reviews
adoptive cell therapies - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Article Snippet: Article Title: Single-cell dynamics of breakthrough toxicities following anakinra prophylaxis for axicabtagene ciloleucel in lymphoma. Article Snippet: Article Title: Context matters: Tumor microenvironments impact cellular therapy success Article Snippet: M.V.M. is an inventor on patents related to adoptive cell therapies, held by MGH (some licensed to Promab) and Article Title: CAR-T cell therapy for the treatment of adult high-grade gliomas Article Snippet: M.V.M. is an inventor on patents related to adoptive Article Title: Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma Article Snippet: M.V.M. is an inventor on patents related to adoptive Article Title: Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS). Article Snippet: Magdi Elsallab (Harvard Medical School, United States) Moataz Ellithi (University of Nebraska Medical Center, United States) Matthew Lunning (Fred and Pamela Buffett Cancer Center at the University of Nebraska Medical Center, United States) Christopher D'Angelo (University of Nebraska Medical Center, United States) Jihyun MA (Department of Biostatistics, University of Nebraska Medical Center, United States) Miguel-Angel Perales (Memorial Sloan Kettering Cancer Center, United States) Matthew Frigault (Massachusetts General Hospital, United States) Marcela Maus (Massachusetts General Hospital, Harvard Medical School, United States) Article Title: Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data. Article Snippet: Chimeric antigen receptor T (CAR T) cell therapies have emerged as a valuable treatment modality for patients with plasma cell disorders.. As the population of patients receiving CAR T therapies grows, the identification and management of associated rare toxicities become increasingly crucial.. This study aims to identify safety signals associated with commercial anti-B-cell maturation antigen (BCMA) CAR T therapies using the Food and Drug Administration Adverse Event Reporting System (FAERS). |